These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32323182)

  • 1. Gut Microbiota and Renal Injury.
    Zhang L; Zhang W; Nie J
    Adv Exp Med Biol; 2020; 1238():93-106. PubMed ID: 32323182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression.
    Mosterd CM; Kanbay M; van den Born BJH; van Raalte DH; Rampanelli E
    Best Pract Res Clin Endocrinol Metab; 2021 May; 35(3):101484. PubMed ID: 33546983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
    Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
    Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.
    Kanbay M; Onal EM; Afsar B; Dagel T; Yerlikaya A; Covic A; Vaziri ND
    Int Urol Nephrol; 2018 Aug; 50(8):1453-1466. PubMed ID: 29728993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney-gut crosstalk in renal disease.
    Colombo I; Aiello-Battan F; Elena R; Ruiz A; Petraglia L; Musso CG
    Ir J Med Sci; 2021 Aug; 190(3):1205-1212. PubMed ID: 33216316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease.
    Feng YL; Cao G; Chen DQ; Vaziri ND; Chen L; Zhang J; Wang M; Guo Y; Zhao YY
    Cell Mol Life Sci; 2019 Dec; 76(24):4961-4978. PubMed ID: 31147751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota-derived tryptophan metabolism mediates renal fibrosis by aryl hydrocarbon receptor signaling activation.
    Liu JR; Miao H; Deng DQ; Vaziri ND; Li P; Zhao YY
    Cell Mol Life Sci; 2021 Feb; 78(3):909-922. PubMed ID: 32965514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gut-kidney-heart axis in chronic kidney disease.
    Sumida K; Kovesdy CP
    Physiol Int; 2019 Sep; 106(3):195-206. PubMed ID: 31560235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease.
    Onal EM; Afsar B; Covic A; Vaziri ND; Kanbay M
    Hypertens Res; 2019 Feb; 42(2):123-140. PubMed ID: 30504819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of gut microbiota: How it could play roles beyond the digestive system on development of cardiovascular and renal diseases.
    Suganya K; Son T; Kim KW; Koo BS
    Microb Pathog; 2021 Mar; 152():104583. PubMed ID: 33164814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease.
    Cosola C; Rocchetti MT; Cupisti A; Gesualdo L
    Pharmacol Res; 2018 Apr; 130():132-142. PubMed ID: 29518493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of gut microbiota-derived metabolites on vascular calcification in CKD.
    Yin L; Li X; Ghosh S; Xie C; Chen J; Huang H
    J Cell Mol Med; 2021 Feb; 25(3):1332-1341. PubMed ID: 33369187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.
    Yang T; Richards EM; Pepine CJ; Raizada MK
    Nat Rev Nephrol; 2018 Jul; 14(7):442-456. PubMed ID: 29760448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota, hypertension and chronic kidney disease: Recent advances.
    Sircana A; De Michieli F; Parente R; Framarin L; Leone N; Berrutti M; Paschetta E; Bongiovanni D; Musso G
    Pharmacol Res; 2019 Jun; 144():390-408. PubMed ID: 29378252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut Microbiome in Chronic Kidney Disease.
    Armani RG; Ramezani A; Yasir A; Sharama S; Canziani MEF; Raj DS
    Curr Hypertens Rep; 2017 Apr; 19(4):29. PubMed ID: 28343357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease.
    Wang S; Lv D; Jiang S; Jiang J; Liang M; Hou F; Chen Y
    Clin Sci (Lond); 2019 Sep; 133(17):1857-1870. PubMed ID: 31467135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiome in chronic kidney disease: challenges and opportunities.
    Nallu A; Sharma S; Ramezani A; Muralidharan J; Raj D
    Transl Res; 2017 Jan; 179():24-37. PubMed ID: 27187743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease.
    Raj D; Tomar B; Lahiri A; Mulay SR
    Pharmacol Res; 2020 Feb; 152():104617. PubMed ID: 31881272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.
    Pan W; Kang Y
    Int Urol Nephrol; 2018 Feb; 50(2):289-299. PubMed ID: 28849345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.